Optimal treatment for patients after myocardial infarction: some current concepts and controversies

Area of Science:

• Cardiology
• Public Health

Background:

• Acute coronary syndromes, including myocardial infarction (MI), are a leading cause of hospitalization globally.
• Approximately 1 million individuals in Poland require medical care post-MI, presenting a significant clinical and social challenge.
• Optimal treatment implementation is crucial for managing MI patients effectively.

Purpose of the Study:

• To review current clinical practice guidelines for post-myocardial infarction (MI) management.
• To assess the adherence to European Society of Cardiology (ESC) recommendations in Poland.
• To highlight the importance of optimal pharmacotherapy and newer treatment options for MI patients.

Main Methods:

• Review of European Society of Cardiology (ESC) clinical practice guidelines.
• Analysis of recent registry data on drug utilization in Poland.
• Discussion of recommended therapeutic strategies including lifestyle modifications and pharmacotherapy.

Main Results:

• Established guidelines emphasize physical activity, smoking cessation, diet, risk factor control, and combination pharmacotherapy.
• Commonly used drugs in Poland include aspirin, clopidogrel, ACE inhibitors, beta-blockers, and statins.
• Recent recommendations advocate for adding omega-3 acid ethyl esters and, in select cases, eplerenone to MI treatment regimens.

Conclusions:

• Optimal treatment for myocardial infarction (MI) patients requires adherence to ESC guidelines, including established and newer pharmacotherapies.
• The integration of omega-3 acid ethyl esters and eplerenone represents an advancement in MI management.
• Ensuring comprehensive and guideline-directed care is paramount for improving patient outcomes in Poland.